EVOLUTION OF CLINICAL MANIFESTATIONS OF WHOOPING COUGH IN CHILDREN IN THE POST-COVID-19 PANDEMIC PERIOD

Authors:

Abstract:

In recent years, an increase in the number of cases of pertussis has been recorded in Europe and Ukraine. The purpose of the study was to find out the features of pertussis in children in the first three years of life after the COVID-19 pandemic and compare them with clinical and laboratory data of similar patients who had pertussis before the pandemic COVID-19. A retrospective analysis of 97 patient charts of inpatients aged 0-36 months diagnosed with pertussis who were treated in the Lviv Regional Clinical Infectious Diseases Hospital in 2017–2019 and 2023–2024 was conducted. It was found that the course of the disease in the post-epidemic cohort was milder, with a higher incidence of respiratory complications; a number of differences in clinical manifestations, complete blood counts in children of different age groups, and in the period before and after the SARS-CoV-2 pandemic were identified. After the end of the COVID-19 pandemic, the weakening of population immunity, genetic mutations of Bordetella pertussis and the possible impact of SARS-CoV-2 infection on the immune response contributed to an increase in children's susceptibility to pertussis and changes in clinical manifestations of the disease.

Keywords:

pertussis children COVID-19 course of disease immune response

References:

1. Bricks LF, Vargas-Zambrano JC, Macina D. Epidemiology of pertussis after the COVID-19 pandemic: analysis of the factors involved in the resurgence of the disease in high-, middle-, and low-income countries. Vaccines (Basel). 2024 Nov 28;12(12):1346. doi: 10.3390/vaccines12121346.
2. Carbonetti NH. Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools. Future Microbiol. 2010;5(3):455-469.
3. Dagenais A, Villalba-Guerrero C, Olivier M. Trained immunity: a “new” weapon in the fight against infectious diseases. Front Immunol. 2023;14:1147476. doi: 10.3389/fimmu.2023.1147476.
4. Deus MC, Gadotti AC, Dias ES, Monte Alegre JB, Van Spitzenbergen BAK, Andrade GB, et al. Prospective variation of cytokine trends during COVID-19: a progressive approach from disease onset until outcome. Int J Mol Sci. 2024;25(19):10578. doi: 10.3390/ijms251910578.
5. Heininger U, Martini H, Eeuwijk J, Prokić I, Guignard AP, Turriani E. et al. Pertactin deficiency of Bordetella pertussis: insights into epidemiology, and perspectives on surveillance and public health impact. Hum Vaccin Immunother. 2024 Dec 31;20(1):2435134. doi:10.1080/21645515.2024.2435134.
6. Hirawat R, Saifi MA, Godugu C. Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications. Life Sci. 2021;267:118923. doi: 10.1016/j.lfs.2020.118923.
7. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM.et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020 Oct 2;370(6512):89-94. doi: 10.1126/science.abd3871.
8. Préziosi MP, Halloran ME. Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness. Vaccine. 2003;21(17-18):1853-1861.
9. Takamatsu Y, Omata K, Shimizu Y, Kinoshita-Iwamoto N, Terada M, Suzuki T. et al. SARS-CoV-2-neutralizing humoral IgA response occurs earlier but is modest and diminishes faster than IgG response. Microbiol Spectr. 2022;10:e02716-22. doi: 10.1128/spectrum.02716-22.
10. Tessier E, Campbell H, Ribeiro S, Rai Y, Burton S, Roy P. et al. Amirthalingam G. Impact of the COVID-19 pandemic on Bordetella pertussis infections in England. BMC Public Health. 2022 Feb 28;22(1):405. doi: 10.1186/s12889-022-12830-9.
11. Van der Donk LEH, Bermejo-Jambrina M, van Hamme JL, Volkers MMW, van Nuenen AC, et al. SARS-CoV-2 suppresses TLR4-induced immunity by dendritic cells via C-type lectin receptor DC-SIGN. PLoS Pathog. 2023 Oct;19(10):e1011735. doi: 10.1371/journal.ppat.1011735.

Publication:

«World of Medicine and Biology» Vol. 21 No. 92 (2025) , с. 48-52
УДК 616.923-053.2

DOI:

https://doi.org/10.26724/2079-8334-2025-2-92-48-52